| Akero Therapeutics: Good Candidate For The MASH Basket | 09/20 15:37 | seekingalpha.com |
| Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH | 09/09 07:00 | globenewswire.com |
| Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference | 08/28 16:05 | globenewswire.com |
| SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO) | 08/23 11:46 | prnewswire.com |
| Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | 08/09 07:00 | globenewswire.com |
| Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade | 07/16 13:05 | zacks.com |
| Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm | 06/28 10:40 | globenewswire.com |
| AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm | 06/25 10:20 | businesswire.com |
| FINAL AKRO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit! | 06/25 05:00 | accesswire.com |